Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.
Slingluff CL Jr, Yamshchikov G, Neese P, Galavotti H, Eastham S, Engelhard VH, Kittlesen D, Deacon D, Hibbitts S, Grosh WW, Petroni G, Cohen R, Wiernasz C, Patterson JW, Conway BP, Ross WG.
Slingluff CL Jr, et al. Among authors: patterson jw.
Clin Cancer Res. 2001 Oct;7(10):3012-24.
Clin Cancer Res. 2001.
PMID: 11595689
Clinical Trial.